PVLA PALVELLA THERAPEUTICS, INC.

8-K Current Report

Filed: February 26, 2026

Health Care

Pharmaceutical Preparations

PALVELLA THERAPEUTICS, INC. (PVLA) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 1.01: Entry into a Material Definitive Agreement

AI Filing Analysis
8-K

Item 1.01 · Entry into a Material Definitive Agreement

• 1,600,000 shares priced at $125.00/share; underwriters hold 30-day option for additional 240,000 shares
• Net proceeds ~$187.3M after underwriting discounts and offering expenses

+3 more insights

Other PALVELLA THERAPEUTICS, INC. 8-K Filings

8-K Feb 24, 2026

Get deeper insights on PALVELLA THERAPEUTICS, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.